Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it ...

A recent study in the Journal of Clinical Medicine found that oral semaglutide significantly improves glycemic control and ...

Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor ...

Merck & Co. agrees to acquire Eyebiotech (EyeBio) for up to $3 billion, a deal that will return the buyer to the eye drug ...

Driven by growing market demand and an improving supply chain, the global weight-loss drug market is expected to hit $150 ...

About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a ...

ANV600 combines a non-blocking αPD-1 antibody and an IL-2Rβ/γ selective agonist targeting IL-2 to tumor-specific T cells resulting in ...

Altimmune is developing pemvidutide, a dual agonist of GLP-1 and glucagon receptors, with promising phase 2 data already seen ...

NRBO READ THE FULL NRBO RESEARCH REPORT Business Update Pre-Clinical MASH Data for DA-1241 to be Presented at EASL Congress ...

For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023.

The cannabinoid CB1 receptor inverse agonist INV-202 (monlunabant) is in clinical studies at Inversago Pharma Inc. as a potentially first-in-class drug for metabolic disorders, including diabetic ...